SEPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Septerna Inc (SEPN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has promising analyst ratings and potential catalysts in the pipeline, the lack of immediate positive trading signals, mixed financial performance, and neutral sentiment from hedge funds and insiders suggest waiting for more clarity on its growth trajectory.
The technical indicators show mixed results. The MACD is above 0 and positively contracting, indicating some bullish momentum. The RSI is neutral at 50.645, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 27.404, with key resistance at 30.219 and support at 24.589.
Analysts have issued multiple buy ratings with price targets ranging from $34 to $43, citing promising pipeline developments like SEP-479 and SEP-631 targeting multi-billion-dollar markets. The company's gross margin remains strong at 100%.
The company's net income and EPS have significantly declined YoY, with net income dropping by -139.82% and EPS down -102.14%. Hedge funds and insiders are neutral, showing no significant trading activity. No recent news or congress trading data is available to provide additional momentum.
In Q3 2025, revenue increased dramatically by 12113.07% YoY to $21.495 million. However, net income dropped to $8.173 million (-139.82% YoY), and EPS fell to 0.18 (-102.14% YoY). The gross margin remains at 100%, showing operational efficiency but struggles with profitability.
Analysts are bullish, with recent price target increases to $35, $34, and $43. They highlight near-term catalysts and promising drug candidates in the pipeline, but these are contingent on future clinical data expected in 2026.
